Non-Therapeutic Biomolecules Market Insights 2025-2034: Growth Forecast and Strategic Priorities

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

Non-Therapeutic Biomolecules Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
Recent years have witnessed a swift expansion of the non-therapeutic biomolecules market. Its size is projected to swell from $30.76 billion in 2024 to $34.23 billion in 2025, showing a compound annual growth rate (CAGR) of 11.3%. This growth during the historic period was driven by factors such as heightening investments in research and development (R&D), expanded use in research and diagnostics, rising consciousness and acceptance, strategic alliances and partnerships, and regulatory backing.

Non-Therapeutic Biomolecules Market Size Forecast: What's the Projected Valuation by 2029?
The market size of non-therapeutic biomolecules is anticipated to experience a swift expansion in the following years, reaching a value of $52.15 billion in 2029 with a compound annual growth rate (CAGR) of 11.1%. This surge during the prediction period can be associated with the emergence of new market opportunities, progress in data analysis and integration, the heightened emphasis on precision medicine, an upswing in investment towards custom healthcare solutions, and a broadening of application areas. Key trends forecasted for this period involve technological innovation, strategic partnerships, growing use in the agricultural sector, an increased application in industrial processes, and a focus on customization and personalization.

View the full report here:
https://www.thebusinessresearchcompany.com/report/non-therapeutic-biomolecules-global-market-report

What Are the Drivers Transforming the Non-Therapeutic Biomolecules Market?
The swift escalation in research and laboratory testing frequency is projected to fuel the expansion of the non-therapeutic biomolecules market in the future. Laboratory examinations comprise medical methods that involve scrutinizing a sample of blood, urine or other bodily substances to identify and monitor illness and formulate a treatment strategy, while research implies the generation of novel knowledge or inventive application of existing knowledge to create new theories, concepts, and comprehension. Non-therapeutic biomolecules are utilized in laboratory tests to identify the presence or concentration of a biomarker molecule indicative of disease which increases the precision and sensitivity of the test. As an example, the National Health Service (NHS), a UK-based hospital and health care provider, reported in July 2024 that diagnostic activity surpassed the pre-pandemic levels in 2023, exhibiting a 21% surge in tests conducted in May 2024 juxtaposed to the preceding year. Thus, the brisk surge in research activities and laboratory testing frequency is stimulating the growth of the non-therapeutic biomolecules market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8769&type=smp

What Long-Term Trends Will Define the Future of the Non-Therapeutic Biomolecules Market?
One key trend that is growing in prominence within the non-therapeutic biomolecules market is product innovation. Major operators in the sector are heavily investing in research and development efforts with a view to creating novel products and maintaining their market standing. An example of this is the recent collaboration in January 2022, between BASF SE, a chemical company based in Germany, and Caregen, a Korean business specializing in biomimetic peptide research and development. The two companies launched the Peptovitae series, which uses liposome encapsulation technology, to broaden BASF's dermo-cosmetics range and to present unique and cutting-edge solutions to a wide array of skin issues. Liposomal encapsulation is a delivery method using fats to transport vital vitamins or medicines to select parts of the body in minute bubbles, without impacting other areas. As a result, the Peptovitae series covers a broader scope of skin problems than is conventionally linked with peptide use, including aging signs, augmenting skin brightness, alleviating skin susceptible to dryness and irritation, and moisturizing the skin.

Which Segments in the Non-Therapeutic Biomolecules Market Offer the Most Profit Potential?
The non-therapeutic biomolecules market covered in this report is segmented -

1) By Trad Pharma: Enzymes, Recombinant Proteins, Plasmids, Peptides, Oligonucleotides, Monoclonal Antibodies
2) By End User: Research, Pharma, In Vitro Diagnostics(IVD)

Subsegments:
1) By Enzymes: Industrial Enzymes, Diagnostic Enzymes
2) By Recombinant Proteins: Antigens, Cytokines, Growth Factors
3) By Plasmids: Research Plasmids, Expression Plasmids
4) By Peptides: Antimicrobial Peptides, Signaling Peptides
5) By Oligonucleotides: Antisense Oligonucleotides, RNAi Oligonucleotides
6) By Monoclonal Antibodies: Research Antibodies, Diagnostic Antibodies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=8769&type=smp

Which Firms Dominate the Non-Therapeutic Biomolecules Market by Market Share and Revenue in 2025?
Major companies operating in the non-therapeutic biomolecules market are Amgen Inc., Genentech Inc., Merck KGaA, Lonza Group AG, Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Charles River Laboratories International Inc., GE Healthcare Life Sciences, Fujifilm Diosynth Biotechnologies, Evonik Industries AG, Seikagaku Corporation, Takeda Pharmaceutical Company Limited, MilliporeSigma, Covance Inc., Sartorius AG, Sanofi S.A., CordenPharma International, Bayer AG, WuXi AppTec, Ginkgo Bioworks, Synlogic Inc., 3M Company, Eppendorf AG, Medtronic Plc, Bio-Techne Corporation, Iovance Biotherapeutics Inc., Vectalys, Avid Bioservices Inc., Sientra Inc.

Which Regions Offer the Highest Growth Potential in the Non-Therapeutic Biomolecules Market?
Asia-Pacific was the largest region in the non-therapeutic biomolecules market share in 2024. The regions covered in the non-therapeutic biomolecules market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8769

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.